Permissionless R&D in Pharma: The IP, Regulatory, and Innovation Strategy Guide Decision-Makers Actually Need
1. Executive Summary Drug development costs roughly double every nine years. That is Eroom’s Law, the inverse of Moore’s Law,
Excipient Switching in Pharma: The Complete IP, Regulatory, and Formulation Strategy Guide
1. Why Excipient Switching Deserves a Seat at the Strategy Table {#1} Pharmaceutical companies spend millions optimizing the active pharmaceutical
Patent Landscaping in Pharma: The Human-Supervised AI Playbook That Actually Works
I. Why Patent Landscaping Is a Core IP Asset, Not a Research Function Patent landscaping has a credibility problem in
Patent Landscaping in Pharma: The Human-Supervised AI Playbook That Actually Works Read Post »
AI-Generated Drugs and the Patent Problem: How to Mine Patent Data for Novel NCEs Without Blowing Your IP Position
1. The $2.6 Billion Bottleneck AI Is Supposed to Fix The standard number is $2.6 billion. That is the capitalized
The Price Floor Problem: How Rock-Bottom Generic Drug Prices Destroy the Supply Chain That Hospitals Depend On
The cheapest medicines in America are also the most dangerous ones to run out of. Generic sterile injectables — levofloxacin,
Pharmaceutical Patent Litigation and Settlements: The Complete Strategic Playbook
Every blockbuster drug carries two price tags: the $2.6 billion average cost of bringing it to market, and the cost
Pharmaceutical Patent Litigation and Settlements: The Complete Strategic Playbook Read Post »
Pfizer’s Portfolio as a Model for Precision in Pharma Investments
The global biopharmaceutical sector has entered a period of profound structural realignment, characterized by the end of the pandemic-driven liquidity
Pfizer’s Portfolio as a Model for Precision in Pharma Investments Read Post »
AI Patent Strategy: Pharma’s Complete Playbook for the $200 Billion Patent Cliff
The numbers are not speculative. Between 2025 and 2029, branded pharmaceutical revenue will fall from $162.8 billion to $67 billion
AI Patent Strategy: Pharma’s Complete Playbook for the $200 Billion Patent Cliff Read Post »
Rucaparib’s Patent Playbook: How One PARP Inhibitor Built a 2035 Exclusivity Wall
The Economic Logic of Pharmaceutical IP: Why Every Dollar Spent on Patents Is a Bet on Survival Biopharma runs on
Rucaparib’s Patent Playbook: How One PARP Inhibitor Built a 2035 Exclusivity Wall Read Post »
